Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Monday. They currently have a $25.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 128.31% from the stock’s current price.
OBSV has been the subject of several other reports. Royal Bank of Canada reaffirmed a “buy” rating and set a $22.00 price objective on shares of Obseva in a research note on Thursday, November 2nd. Credit Suisse Group began coverage on shares of Obseva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 target price for the company. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Wednesday, October 18th. Finally, BMO Capital Markets began coverage on shares of Obseva in a research note on Monday, December 4th. They set an “outperform” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.00.
Obseva (NASDAQ OBSV) traded down $0.05 during mid-day trading on Monday, hitting $10.95. 48,849 shares of the company were exchanged, compared to its average volume of 45,594. Obseva has a 1 year low of $5.00 and a 1 year high of $14.69.
Institutional investors and hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. raised its holdings in shares of Obseva by 12.4% in the third quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock valued at $2,118,000 after acquiring an additional 28,700 shares in the last quarter. VHCP Management II LLC raised its holdings in shares of Obseva by 834.2% in the third quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock valued at $11,407,000 after acquiring an additional 1,251,343 shares in the last quarter. Abingworth LLP bought a new stake in shares of Obseva in the third quarter valued at about $3,480,000. Iguana Healthcare Management LLC raised its holdings in shares of Obseva by 66.7% in the third quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after acquiring an additional 20,000 shares in the last quarter. Finally, First Manhattan Co. bought a new stake in shares of Obseva in the fourth quarter valued at about $9,760,000. 38.61% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Obseva (OBSV) Stock Rating Reaffirmed by HC Wainwright” was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/05/obseva-obsv-stock-rating-reaffirmed-by-hc-wainwright.html.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.